PDPHF (Egetis Therapeutics AB) Total Inventories: $0.19 Mil (As of Mar. 2026)


PDPHF Egetis Therapeutics AB PDPHF
24 GF Score
Price $0.64
GF Value $0.64
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Total Inventories?

Egetis Therapeutics AB PDPHF 24 Total Inventories is $0.19 Mil as of Mar. 2026. GuruFocus rates PDPHF with a GF Score™ of 24/100 and a GF Value™ of $0.64 (Fairly Valued). The stock has 5 warning signs investors should review.

Egetis Therapeutics AB's total inventories for the quarter that ended in Mar. 2026 was $0.19 Mil. Egetis Therapeutics AB's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $0.22 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Egetis Therapeutics AB's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $-0.04.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Egetis Therapeutics AB's Days Inventory for the three months ended in Mar. 2026 was 13.76.

Inventory Turnover measures how fast the company turns over its inventory within a year. Egetis Therapeutics AB's Inventory Turnover for the quarter that ended in Mar. 2026 was 6.63.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Egetis Therapeutics AB's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.15.

Egetis Therapeutics AB  (OTCPK:PDPHF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Egetis Therapeutics AB's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is

Net-Net Working Capital Per Share (Q: Mar. 2026 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(15.294+0.75 * 0.558+0.5 * 0.193-30.996
-0-0)/395.163
=-0.04

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Egetis Therapeutics AB's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=0.22/1.459*365 / 4
=13.76

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Egetis Therapeutics AB's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2026 ) / Average Total Inventories (Q: Mar. 2026 )
=1.459 / 0.22
=6.63

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Egetis Therapeutics AB's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=0.22 / 1.438
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Egetis Therapeutics AB Total Inventories Related Terms

Egetis Therapeutics AB Total Inventories Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Total Inventories Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.06 0.07 0.09 0.25

Egetis Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.15 0.12 0.25 0.19
PDPHF
24GF Score
Egetis Therapeutics AB PDPHF
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egetis Therapeutics AB Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.19 Mil mean?
Egetis Therapeutics AB (PDPHF) has a Total Inventories of $0.19 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Egetis Therapeutics AB and its competitors.
Is Egetis Therapeutics AB's Total Inventories too high?
Egetis Therapeutics AB's current Total Inventories is $0.19 Mil. Overall, Egetis Therapeutics AB has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Total Inventories compare to VRTX and REGN?
Egetis Therapeutics AB's Total Inventories of $0.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current Total Inventories is $0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (PDPHF) is currently considered Fairly Valued. The stock's GF Value™ is $0.64, compared to a current price of $0.64 — trading 0.7% below its estimated fair value. The current Total Inventories is $0.19 Mil. Egetis Therapeutics AB's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Egetis Therapeutics AB (PDPHF), the current Total Inventories is $0.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (PDPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be undervalued. The current stock price of $0.64 is trading 0.7% below its estimated GF Value™ of $0.64. GuruFocus considers Egetis Therapeutics AB to be Fairly Valued.

Key valuation signals for PDPHF:

  • Total Inventories: $0.19 Mil
  • GF Value™: $0.64 vs. price of $0.64 (0.7% below fair value)
  • GF Score™: 24/100 with 5 warning signs

No single metric tells the full story. See the PDPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
24GF Score

Get the complete analysis for PDPHF

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price
$0.64
GF Value